Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Weight Loss Stack
Peptide Schedule Research Team
Combine GLP-1 appetite suppression with targeted fat metabolism. Semaglutide reduces hunger at the brain level while AOD-9604 specifically targets fat breakdown without affecting blood sugar or growth.
- Semaglutide Grade A Research Strong Community Strong
- AOD-9604 Grade B Research Weak Community Moderate
14.9% of body weight gone in 68 weeks. That number, from the STEP 1 trial (PMID 33567185, n=1,961), turned semaglutide into the most prescribed weight loss drug in modern medicine. Semaglutide (CAS 910463-68-2) is a GLP-1 receptor agonist sold as Ozempic, Wegovy, Wegovy HD, and Rybelsus.
The drug mimics incretin hormone GLP-1. It binds receptors in the pancreas, the gut, and satiety centers in the hypothalamus. Pancreatic binding increases insulin secretion. Gut binding slows gastric emptying. Brain binding turns down hunger signals. An albumin-binding fatty acid side chain extends the half-life to roughly 7 days, allowing once-weekly dosing.
Real-world use spans three FDA indications. Obesity patients follow the Wegovy titration from 0.25 mg up to 2.4 mg weekly (or 7.2 mg with the high-dose label approved March 2026). Type 2 diabetics typically land between 0.5 and 2.0 mg weekly on the Ozempic label. Cardiovascular patients stay at 2.4 mg long-term after SELECT (PMID 37952131) confirmed a 20% reduction in major adverse cardiovascular events across 17,604 participants.
Community experience tracks the clinical data closely. Over 350,000 combined members across r/Ozempic and r/semaglutide consistently report appetite suppression, steady 1 to 2 lbs per week weight loss, and reduced food noise within the first month. The honest caveat: two-thirds of the weight returns within a year of stopping (STEP 1 extension data). Lean mass loss of 25 to 40% without resistance training is well-documented. This is a long-term commitment, not a quick fix.
In SURMOUNT-5 (PMID 40353578, n=751), semaglutide produced 13.7% weight loss versus 20.2% for tirzepatide at 72 weeks, with everyone on the highest dose they tolerated. Semaglutide holds the stronger cardiovascular outcomes dataset: the SELECT trial (PMID 37952131, n=17,604) confirmed a 20% reduction in major adverse cardiovascular events over 39.8 months.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 250 mcg | Weekly |
| Moderate | 500 mcg | Weekly |
| Aggressive | 2.4 mg | Weekly |
About 2.6 kg of weight loss over 12 weeks on 1 mg a day by mouth, versus about 0.8 kg on placebo. That was the best arm of a 12-week trial of the AOD-9604 peptide (also called hGH fragment 177-191 or hGH frag, CAS 221231-10-3) in 300 obese adults. It was published only as a 2005 meeting abstract (Herd et al., Obesity Research). FDA's December 2024 PCAC briefing gives the rates: 0.22 kg a week versus 0.07 kg on placebo. Then the larger Phase IIb trial with 536 subjects ran for 24 weeks, added strict diet and exercise controls, and missed its primary endpoint. Metabolic Pharmaceuticals terminated the program in 2007.
How AOD-9604 works is still unsettled. Unlike full-length growth hormone, it does not bind the GH receptor (PMID 11673763). Blood sugar stays flat. IGF-1 stays flat. Beta-3 adrenergic receptors seem to matter, but AOD-9604 has not been shown to activate them (details under How AOD-9604 Works). FDA's 2024 briefing says the molecular target is still unknown.
Community use looks different from the clinical program. Most users inject 300 to 500 mcg subcutaneously each morning on an empty stomach. Users usually justify that range by converting the 1 mg oral clinical dose with an assumed 40% oral bioavailability. FDA's 2024 briefing calls oral bioavailability unclear even in animals, and no human SC pharmacokinetic study exists. Across 50 to 150 Reddit threads in r/Peptides, the consensus is consistent: AOD-9604 is a mild add-on, not a primary fat loss tool. It performs best when stacked with CJC-1295 and Ipamorelin in a caloric deficit. Anyone expecting GLP-1-level results will be disappointed.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200 mcg | Daily |
| Moderate | 300 mcg | Daily |
| Aggressive | 500 mcg | Daily |
Interactions
Complementary weight loss mechanisms. Semaglutide suppresses appetite via GLP-1, AOD-9604 directly targets fat metabolism without overlapping pathways.
Protocol Tips
- Titrate Semaglutide slowly — start at 250mcg/week.
- AOD-9604 should be dosed on an empty stomach.
- Prioritize protein intake to preserve lean muscle.
- See our GLP-1 titration tool for the full Semaglutide schedule.
Related Guides & Comparisons
Beginner-tier doses from each peptide's page load into a preview you can change.